Clough Capital Partners’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Clough Capital Partners’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,137,764	Closed	-$3.63M	–	132
2022 Q1	$3.63M	Sell	1,137,764 -168,862	-13%	-$486K	0.28%	73
2021 Q4	$3.75M	Sell	1,306,626 -260,700	-17%	-$971K	0.25%	68
2021 Q3	$6.22M	Hold	1,567,326	–	–	0.38%	63
2021 Q2	$9.34M	Buy	1,567,326 +215,013	+16%	+$1.52M	0.51%	68
2021 Q1	$16.4M	Buy	1,352,313 +19,916	+1%	+$283K	0.73%	53
2020 Q4	$19.4M	Buy	1,332,397 +19,111	+1%	+$243K	1.38%	26
2020 Q3	$14.9M	Buy	+1,313,286	New	+$16.8M	1.07%	31

Clough Capital Partners's CMPI Position: Q2 2022 in Review

Clough Capital Partners sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 1,137,764 shares — an estimated $3.63M sold.

Clough Capital Partners first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $19.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Clough Capital Partners reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Clough Capital Partners sold 1,137,764 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $3.63M.
Clough Capital Partners first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Clough Capital Partners's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $19.4M in Q4 2020.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Clough Capital Partners's 13F filing for Q2 2022, filed 16 Aug 2022.